CNMD · Conmed Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.37B | $1.31B | $1.24B | $1.05B | $1.01B | $862.46M |
| Cost of Revenue | $624.25M | $573.98M | $568.50M | $474.23M | $442.60M | $402.16M |
| Gross Profit | $750.48M | $733.03M | $676.25M | $571.25M | $568.04M | $460.30M |
| R&D | $55.88M | $54.43M | $52.60M | $47.15M | $43.56M | $40.47M |
| SG&A | $591.97M | $478.28M | $503.04M | $454.04M | $414.75M | $373.82M |
| Total Operating Expenses | $647.85M | $532.71M | $555.64M | $501.19M | $458.32M | $414.29M |
| D&A | $17.14M | $16.61M | $16.20M | $16.05M | $16.49M | $18.04M |
| Operating Income | $102.62M | $200.33M | $120.60M | $70.05M | $109.72M | $46.01M |
| Interest Expense | $31.09M | $37.30M | $39.77M | $28.91M | $35.48M | $44.05M |
| Income Tax | $24.06M | $30.61M | $16.37M | $9.72M | $10.56M | ($7.91M) |
| Net Income | $47.05M | $132.42M | $64.46M | ($80.58M) | $62.54M | $9.52M |
| EPS - Basic | $1.52 | $4.29 | $2.10 | ($2.68) | $2.14 | $0.33 |
| EPS - Diluted | $1.51 | $4.25 | $2.04 | ($2.68) | $1.94 | $0.32 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $40.82M | $24.46M | $24.30M | $28.94M | $20.85M | $32.62M |
| Accounts Receivable | $247.83M | $237.73M | $242.28M | $191.34M | $183.88M | $177.15M |
| Inventory | $355.54M | $346.72M | $318.32M | $332.32M | $231.64M | $194.87M |
| Accounts Payable | $93.65M | $102.25M | $88.22M | $73.39M | $58.20M | $53.31M |
| Current Assets | $672.86M | $640.01M | $615.65M | $581.23M | $460.12M | $416.65M |
| Total Assets | $2.33B | $2.31B | $2.30B | $2.30B | $1.77B | $1.75B |
| Current Liabilities | $315.04M | $278.13M | $310.73M | $296.55M | $196.65M | $190.20M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $1.29B | $1.34B | $1.47B | $1.55B | $980.58M | $1.04B |
| Stockholders' Equity | $1.03B | $962.68M | $834.22M | $745.54M | $785.43M | $709.04M |
| Retained Earnings | $588.77M | $560.28M | $452.53M | $412.63M | $496.61M | $457.42M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $170.69M | $166.97M | $125.35M | $33.37M | $111.77M | $64.53M |
| Investing Cash Flow | ($20.96M) | ($13.08M) | ($20.03M) | ($249.53M) | ($14.87M) | ($13.64M) |
| Financing Cash Flow | ($135.82M) | ($151.00M) | ($110.43M) | $225.00M | ($101.55M) | ($52.06M) |
| CapEx | $19.81M | $13.08M | $19.03M | $21.79M | $14.87M | $13.01M |
| Free Cash Flow | $150.88M | $153.88M | $106.32M | $11.58M | $96.90M | $51.52M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 54.6% | 56.1% | 54.3% | 54.6% | 56.2% | 53.4% |
| Operating margin | 7.5% | 15.3% | 9.7% | 6.7% | 10.9% | 5.3% |
| EBITDA margin | 8.7% | 16.6% | 11.0% | 8.2% | 12.5% | 7.4% |
| Net margin | 3.4% | 10.1% | 5.2% | -7.7% | 6.2% | 1.1% |
| Free cash flow margin | 11.0% | 11.8% | 8.5% | 1.1% | 9.6% | 6.0% |
| FCF / Net income | 3.21 | 1.16 | 1.65 | -0.14 | 1.55 | 5.41 |
| R&D / Revenue | 4.1% | 4.2% | 4.2% | 4.5% | 4.3% | 4.7% |
| SG&A / Revenue | 43.1% | 36.6% | 40.4% | 43.4% | 41.0% | 43.3% |
| Effective tax rate | 33.8% | 18.8% | 20.3% | - | 14.4% | -493.7% |
| Return on assets | 2.0% | 5.7% | 2.8% | -3.5% | 3.5% | 0.5% |
| Return on equity | 4.6% | 13.8% | 7.7% | -10.8% | 8.0% | 1.3% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.14 | 2.30 | 1.98 | 1.96 | 2.34 | 2.19 |
| Quick ratio | 1.01 | 1.05 | 0.96 | 0.84 | 1.16 | 1.17 |
| Cash ratio | 0.13 | 0.09 | 0.08 | 0.10 | 0.11 | 0.17 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | 3.3x | 5.4x | 3.0x | 2.4x | 3.1x | 1.0x |
| Equity multiplier | 2.25 | 2.40 | 2.76 | 3.08 | 2.25 | 2.47 |
| Liabilities / Assets | 0.56 | 0.58 | 0.64 | 0.68 | 0.56 | 0.60 |
| Efficiency | ||||||
| Asset turnover | 0.59 | 0.57 | 0.54 | 0.46 | 0.57 | 0.49 |
| Inventory turnover | 1.76 | 1.66 | 1.79 | 1.43 | 1.91 | 2.06 |
| Days sales outstanding | 66d | 66d | 71d | 67d | 66d | 75d |
| Days inventory outstanding | 208d | 220d | 204d | 256d | 191d | 177d |
| Days payable outstanding | 55d | 65d | 57d | 56d | 48d | 48d |
| Cash conversion cycle | 219d | 222d | 219d | 266d | 209d | 203d |
| Valuation | ||||||
| P / E | 26.9x | 16.1x | 53.7x | - | 73.1x | 350.0x |
| P / B | 1.2x | 2.2x | 4.1x | 3.6x | 5.8x | 4.7x |
| P / S | 0.9x | 1.6x | 2.8x | 2.5x | 4.5x | 3.8x |
| EV / EBITDA | 10.2x | 9.7x | 25.1x | 30.6x | 36.0x | 51.0x |
| Growth | ||||||
| Revenue growth (YoY) | 5.2% | 5.0% | 19.1% | 3.4% | 17.2% | -9.7% |
| Revenue CAGR (3y) | 9.6% | 9.0% | 13.0% | 3.1% | 9.8% | 2.7% |
| Revenue CAGR (5y) | 9.8% | 6.5% | 10.3% | 5.6% | 5.8% | 3.7% |
| Gross profit growth (YoY) | 2.4% | 8.4% | 18.4% | 0.6% | 23.4% | -12.3% |
| Operating income growth (YoY) | -48.8% | 66.1% | 72.2% | -36.2% | 138.5% | -41.8% |
| Net income growth (YoY) | -64.5% | 105.4% | - | - | 557.2% | -66.7% |
| EPS growth (YoY) | -64.5% | 108.3% | - | - | 506.2% | -67.0% |
| EPS CAGR (3y) | - | 29.9% | 85.4% | - | 11.2% | -45.4% |
| EPS CAGR (5y) | 36.4% | 34.4% | 7.7% | - | 30.1% | -21.7% |
| FCF growth (YoY) | -2.0% | 44.7% | 818.1% | -88.1% | 88.1% | -31.4% |
| FCF CAGR (5y) | 24.0% | 15.4% | 12.8% | -26.2% | 32.8% | 9.3% |
| Book value growth (YoY) | 7.3% | 15.4% | 11.9% | -5.1% | 10.8% | -0.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$1.32B totalGeneral Surgery$789.74M · 59.9%
Orthopedic Surgery$529.12M · 40.1%
Geographic
$1.37B totalUS$774.59M · 56.3%
EMEA$264.65M · 19.3%
Asia Pacific$208.72M · 15.2%
Americasexcludingthe United States$126.76M · 9.2%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.39
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Electromedical & Electrotherapeutic Apparatus
Comparing CONMED Corp against the 5 most active filers in the same SIC group.
Dividends
$0.40/share trailing 12 months · -50.0% YoY
| Ex-date | Per share |
|---|---|
| Sep 15, 2025 | $0.2000 |
| Jun 13, 2025 | $0.2000 |
| Mar 14, 2025 | $0.2000 |
| Dec 20, 2024 | $0.2000 |
| Sep 16, 2024 | $0.2000 |
| Jun 14, 2024 | $0.2000 |
| Mar 14, 2024 | $0.2000 |
| Dec 15, 2023 | $0.2000 |
| Sep 14, 2023 | $0.2000 |
| Jun 14, 2023 | $0.2000 |
| Mar 14, 2023 | $0.2000 |
| Dec 15, 2022 | $0.2000 |
| Sep 14, 2022 | $0.2000 |
| Jun 14, 2022 | $0.2000 |
| Mar 14, 2022 | $0.2000 |
| Dec 14, 2021 | $0.2000 |
| Sep 14, 2021 | $0.2000 |
| Jun 14, 2021 | $0.2000 |
| Mar 12, 2021 | $0.2000 |
| Dec 14, 2020 | $0.2000 |
| Sep 14, 2020 | $0.2000 |
| Jun 12, 2020 | $0.2000 |
| Mar 13, 2020 | $0.2000 |
| Dec 12, 2019 | $0.2000 |